Trials / Recruiting
RecruitingNCT07084662
Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Xinlikang Capsule in the Treatment of Chemotherapy-induced Fatigue and Immune Disorders in Patients With Diffuse Large B Lymphoma
- Status
- Recruiting
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of Xinlikang capsule in the treatment of cancer-related fatigue (CRF) and peripheral blood lymphocytes in patients with diffuse large B-cell lymphoma (DLBCL) who achieved complete remission (CR) after all courses of chemotherapy-containing regimens
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xinlikang capsules | Xinlikang capsules after meals, 5 capsules each time, 3 times a day for 12 weeks |
| DRUG | mimic capsules | mimic capsules, 5 capsules each time after meals, 3 times a day for 12 weeks. |
Timeline
- Start date
- 2025-09-11
- Primary completion
- 2028-08-01
- Completion
- 2030-08-01
- First posted
- 2025-07-24
- Last updated
- 2025-11-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07084662. Inclusion in this directory is not an endorsement.